What is Hibercell?
Hibercell is a clinical-stage biopharmaceutical company focused on developing novel therapies that target adaptive-stress driven vulnerabilities within cancer cells. This approach aims to overcome treatment resistance, prevent cancer relapse, and inhibit metastasis. The company's therapeutic candidates, including HC-7366, HC-5404, and Odetiglucan, are designed to exploit these stress-induced vulnerabilities to improve patient outcomes. HiberCell's leadership comprises experienced biotech executives who integrate traditional drug development methodologies with advanced computational expertise. The company's core mission is to pioneer new treatment paradigms and enhance the lives of cancer patients.
How much funding has Hibercell raised?
Hibercell has raised a total of $158.2M across 3 funding rounds:
Series A
$60.8M
Series B
$67.4M
Debt
$30M
Series A (2019): $60.8M with participation from ARCH Venture Partners, Celgene Corporation, 6 Dimensions Capital, and Hillhouse Capital
Series B (2021): $67.4M led by Bristol-Myers Squibb, Mount Sinai Health System, Magnetic Ventures, Monashee Investment Management, Trinitas Capital Management, Hercules Capital, Huizenga Capital Management, Tekla Healthcare Opportunities, and ARCH Venture Partners
Debt (2021): $30M supported by Hercules Capital
Key Investors in Hibercell
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical organization focused on discovering, developing, and manufacturing prescription medications for serious patient needs, with expertise in oncology, cardiovascular disease, immunoscience, and virology. They are committed to advancing cancer immunotherapies and other critical treatments.
Mount Sinai Health System
The Mount Sinai Health System is an integrated healthcare provider and biomedical research institution, offering comprehensive care across seven hospital campuses and a medical school, dedicated to advancing medical education and patient outcomes.
Magnetic Ventures
Magnetic Ventures is a female-founded venture capital firm specializing in early-stage healthcare innovation, leveraging AI, machine learning, and next-gen biotech to support deep technology transformations in the life sciences sector.
What's next for Hibercell?
With its recent major strategic investment and substantial total funding, Hibercell is well-positioned for its next phase of growth. The company's focus on clinical-stage therapeutic candidates suggests a trajectory towards further clinical trials and potential regulatory submissions. The strategic nature of the recent investment indicates strong confidence from backers in Hibercell's innovative approach to cancer treatment, likely enabling the company to accelerate its research and development pipeline, expand its operational capabilities, and potentially forge new partnerships within the oncology sector. This capital infusion is critical for advancing its drug candidates through rigorous testing and toward commercialization, aiming to address significant unmet needs in cancer therapy.
See full Hibercell company page
